Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Effect of insulin on plasma vascular endothelial growth factor in children with new-onset diabetes.

Ashraf A, Mick G, Meleth S, Abdullatif H, Wang X, McCormick K.

J Clin Endocrinol Metab. 2005 Aug;90(8):4920-3. Epub 2005 May 24.

PMID:
15914522
2.

Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.

Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A.

Diabet Med. 2000 Sep;17(9):650-6.

PMID:
11051284
3.

Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus.

Seckin D, Ilhan N, Ilhan N, Ertugrul S.

Diabetes Res Clin Pract. 2006 Aug;73(2):191-7. Epub 2006 Jan 26.

PMID:
16442660
4.

The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients.

Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, Yamamoto K, Kato T, Ono Y, Nagata M, Hayakawa N, Suzuki A, Goto Y, Oda N.

Metabolism. 2004 May;53(5):550-5.

PMID:
15131756
5.

Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications.

Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, Verrotti A.

J Pediatr. 1999 Apr;134(4):486-91.

PMID:
10190925
6.

VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes.

Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, Wiersinga WM.

Diabetes Care. 2013 Jun;36(6):1629-34. doi: 10.2337/dc12-1951. Epub 2013 Jan 15.

7.

Insulin treatment reduces pre-prandial plasma ghrelin concentrations in children with type 1 diabetes.

Ashraf A, Mick G, Meleth S, Wang X, McCormick K.

Med Sci Monit. 2007 Dec;13(12):CR533-7.

PMID:
18049431
8.
9.

Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy.

Zehetner C, Kirchmair R, Kralinger M, Kieselbach G.

Acta Ophthalmol. 2013 Sep;91(6):e470-3. doi: 10.1111/aos.12081. Epub 2013 Mar 4.

10.

Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity.

Kristensen PL, Høi-Hansen T, Boomsma F, Pedersen-Bjergaard U, Thorsteinsson B.

Metabolism. 2009 Oct;58(10):1430-8. doi: 10.1016/j.metabol.2009.04.026. Epub 2009 Jul 1.

PMID:
19573885
11.

Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus.

Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR.

Pediatr Diabetes. 2008 Feb;9(1):9-16. doi: 10.1111/j.1399-5448.2007.00243.x.

PMID:
18211631
12.

The Increased Circulating Plasma Levels of Vascular Endothelial Growth Factor in Patients with Type 1 Diabetes Do Not Correlate to Metabolic Control.

Singh K, Sandler S, Espes D.

J Diabetes Res. 2017;2017:6192896. doi: 10.1155/2017/6192896. Epub 2017 Mar 21.

13.

Glycemic control and insulin requirements in type 1 diabetic patients depending on the clinical characteristics at diabetes onset.

Beato-Víbora PI, Tormo-García MÁ.

Endocr Res. 2014;39(2):86-90. doi: 10.3109/07435800.2013.840651. Epub 2013 Oct 23.

PMID:
24152206
14.

Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis.

Redondo MJ, Connor CG, Ruedy KJ, Beck RW, Kollman C, Wood JR, Buckingham B, Klingensmith GJ, Silverstein J, Tamborlane WV; Pediatric Diabetes Consortium.

Pediatr Diabetes. 2014 Jun;15(4):294-302. doi: 10.1111/pedi.12061. Epub 2013 Jul 24.

15.

Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus.

Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J.

Pediatr Diabetes. 2008 Oct;9(5):472-9. doi: 10.1111/j.1399-5448.2008.00390.x. Epub 2008 Aug 20.

PMID:
18721168
16.

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy.

Hanefeld M, Appelt D, Engelmann K, Sandner D, Bornstein SR, Ganz X, Henkel E, Haase R, Birkenfeld AL.

Horm Metab Res. 2016 Aug;48(8):529-34. doi: 10.1055/s-0042-106295. Epub 2016 Jul 7. Erratum in: Horm Metab Res. 2016 Sep;48(9):620.

PMID:
27388431
17.

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ.

Circulation. 2011 Aug 2;124(5):555-62. doi: 10.1161/CIRCULATIONAHA.111.018259. Epub 2011 Jul 18.

18.

Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus.

Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS.

Pediatr Res. 1998 Dec;44(6):873-5.

PMID:
9853920
19.

Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009.

de Beaufort CE, Lange K, Swift PG, Aman J, Cameron F, Castano L, Dorchy H, Fisher LK, Hoey H, Kaprio E, Kocova M, Neu A, Njolstad PR, Phillip M, Schoenle E, Robert JJ, Urukami T, Vanelli M, Danne T, Barrett T, Chiarelli F, Aanstoot HJ, Mortensen HB; Hvidoere Study Group.

Pediatr Diabetes. 2013 Sep;14(6):422-8. doi: 10.1111/j.1399-5448.2012.00922.x. Epub 2012 Sep 10. Erratum in: Pediatr Diabetes. 2014 May;15(3):260.

PMID:
22957743
20.

Supplemental Content

Support Center